FASN has been identified as a poor prognostic factor in patients with colon cancer, cervical cancer, cholangiocarcinoma, and clear cell renal cell carcinoma (Yuan et al. 2020; Tomacha et al. 2021; Drury et al. 2022; Du et al. 2022). This evidence concerns the gene FASN and cervical carcinoma.